Product Description
SAB01 inhibits c-Kit, a validated target on the mast cells that drive a variety of allergic diseases. Historically this target has had toxicity limitations including infections, neutropenia and low sperm counts due to its expression on a variety of other cell types. To overcome this, Santa Ana designed a bi-specific that conditionally blocks c-Kit only in the presence of an undisclosed anchor target shown to be restricted to mast cells. In vitro and in vivo, SAB01 showed conditional activity against mast cells. SAB01 has been named as a development candidate, with Phase I testing expected to start next year in chronic inducible urticaria. (Sourced from: https://www.santaanabio.com/pipeline)
Mechanisms of Action: C-Kit Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Santaana bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Chronic Spontaneous Urticaria
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|